A variety of immune parameters have been found to be related to the response of EGFR mutant tumors to immunotherapy, including PD-L1 expression, tumor mutation burden (TMB), the human leukocyte antigen (HLA)-T-cell receptor (TCR) axis, tumor metabolic factors, tumor-infiltrating lymphocytes (TILs), immune cell infiltration, and soluble molecules [45]. This evidence concerns the gene CD274 and neoplasm.